179334-10-2

Basic information

• Product Name: (3-FLUORO-PHENYL)-PIPERAZIN-1-YL-METHANONE
• Synonyms: 1-(3-FLUOROBENZOYL)PIPERAZINE;3-FLUOROBENZOIC ACID, PIPERAZIDE;(3-FLUORO-PHENYL)-PIPERAZIN-1-YL-METHANONE
• CAS NO: 179334-10-2
• Molecular Formula: C₁₁H₁₃FN₂O
• Molecular Weight: 208.23
• Mol File: 179334-10-2.mol

Chemical Properties

• Boiling Point: 352.8°C at 760 mmHg
• Flash Point: 167.2°C
• Appearance: /
• Density: 1.191g/cm³
• Vapor Pressure: 3.73E-05mmHg at 25°C
• Refractive Index: 1.541
• CAS DataBase Reference: (3-FLUORO-PHENYL)-PIPERAZIN-1-YL-METHANONE(CAS DataBase Reference)
• NIST Chemistry Reference: (3-FLUORO-PHENYL)-PIPERAZIN-1-YL-METHANONE(179334-10-2)
• EPA Substance Registry System: (3-FLUORO-PHENYL)-PIPERAZIN-1-YL-METHANONE(179334-10-2)

Safety Data

• Hazard Codes: Xi,Xn
• Statements: 22
• HazardClass: IRRITANT
• Hazardous Substances Data: 179334-10-2(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Research:
(3-FLUORO-PHENYL)-PIPERAZIN-1-YL-METHANONE is used as a pharmacological research reagent for studying its interactions with biological systems and exploring its potential therapeutic applications.
Used in Chemical Synthesis:
(3-FLUORO-PHENYL)-PIPERAZIN-1-YL-METHANONE is used as a starting material for the synthesis of other compounds, potentially leading to the development of new drugs or chemical products.

InChI:InChI=1/C11H13FN2O/c12-10-3-1-2-9(8-10)11(15)14-6-4-13-5-7-14/h1-3,8,13H,4-7H2

Upstream product

• 1711-07-5 3-fluorobenzoyl chloride 
• 142-64-3 piperazine dihydrochloride 
• 776-71-6 1-(3-fluorobenzoyl) imidazole 
• 110-85-0 piperazine 
• 455-38-9 3-fluorobenzoic acid 
• 1071521-63-5 tert-butyl 4-(3-fluorobenzoyl)piperazine-1-carboxylate 

Downstream Products

• 1071518-29-0 4-(3-fluorobenzoyl)piperazine-1-carboxylic acid (5-methylisoxazol-3-yl)amide 
• 1071518-81-4 4-(3-fluorobenzoyl)piperazine-1-carboxylic acid [3-(4-methyl-4H-[1,2,4]triazol-3-yl)phenyl]amide 
• 1071517-47-9 4-(3-fluorobenzoyl)piperazine-1-carboxylic acid (3-chloro-4-morpholin-4-ylphenyl)amide 
• 1071520-42-7 4-(3-fluorobenzoyl)piperazine-1-carboxylic acid (3-fluoro-4-nitrophenyl)amide 

Relevant articles and documents

Looking toward the Rim of the Active Site Cavity of Druggable Human Carbonic Anhydrase Isoforms

We report the synthesis and biochemical evaluation of a series of substituted 4-(4-aroylpiperazine-1-carbonyl)benzenesulfonamides (5a-s) developed as inhibitors of druggable carbonic anhydrase (CA) isoforms, as tools for the identification of new therapeu

Expanding the structural diversity of Bcr-Abl inhibitors: Hybrid molecules based on GNF-2 and Imatinib

In order to expand the structural diversity of Bcr-Abl inhibitors, twenty hybrids (series E and P) have been synthesized and characterized based on Imatinib and GNF-2. Their biological activities were evaluated in vitro against human leukemia cells. Most compounds exhibited potent antiproliferative activity against K562 cells, especially for compounds E4, E5 and E7. Furthermore, these new hybrids were also screened for Abl kinase inhibitory activity, and some of them inhibited Abl kinase with low micromolar IC50 values. In particular, compound P3 displayed the most potent activity with IC50 value of 0.017 μM comparable with that of Imatinib. Molecular docking studies indicated that these novel hybrids fitted well with the active site of Bcr-Abl. These results suggested the great potential of these compounds as novel Bcr-Abl inhibitors.

Synthesis and biological evaluation of novel aromatic-heterocyclic biphenyls as potent anti-leukemia agents

As a continuation to our previous research, twenty-eight aromatic-heterocyclic biphenyls were designed and synthesized as novel Bcr-Abl inhibitors. The title compounds were investigated for their antiproliferative activities against wild K562 cells and Imatinib-resistant K562 cells (K562R). The results indicated that most of them exhibited potent Bcr-Abl inhibition and moderate antiproliferative potency against K562 cells. Furthermore, three compounds 3, 7 and 21 displayed moderate antiproliferative activities against K562R cells. Molecular docking indicated that 3 bound more tightly with Bcr-AblT315I compared to Bcr-AblWT. The higher affinity was consistent with its relatively promising K562R cell growth inhibition. These aromatic-heterocyclic biphenyls could be considered as novel lead compound for optimized as Bcr-AblT315I inhibitors. They provide a good starting point for the further development of novel anti-leukemia agents capable of dealing with clinical acquired resistance against Imatinib.

Imidazole-catalyzed monoacylation of symmetrical diamines

Figure Presented. An imidazole-catalyzed protocol for monoacylation of symmetrical diamines has been developed. The protocol gave selective monoacylation of aliphatic (cyclic and acyclic) primary and secondary diamines. In the reaction, imidazole acts as both catalyst and a leaving group. Different monoacylated piperazines and other diamines were synthesized at room temperature in an ethanol/water solvent system.

PIPERAZINE COMPOUNDS FOR THE INHIBITION OF HAEMATOPOIETIC PROSTAGLANDIN D SYNTHASE

The present invention relates to compounds of general formula (I): wherein A, Y, X, n and B are as defined herein; and their use in the treatment and prevention of metabolic disorders, inflammatory conditions, allergic conditions, fever, pain including allodynia and nociception, eating disorders, cachexia, brain injuries, cancer of the genitals, sleep apnoea, cardiovascular disease, flush effect associated with nicotinic acid and related compounds or for the promotion of wound healing. Certain compounds of general formula (I) are new and the invention also relates to these compounds and to their use in medicine.

Certain substituted 1-aryl-3-piperazin-1′-yl propanones

Disclosed are compounds of formula I: wherein X is a carbonyl, sulfonyl, methylene, or methylene substituted with optionally substituted phenyl; Z is nitrogen or CH; Ar1and Ar2independently represent aryl groups; and Y is hydrogen; o

Certain substituted 1-aryl-3-piperazin-1'-yl propanones to treat Alzheimer's Disease

Disclosed are compounds of formula I: STR1 or the pharmaceutically acceptable salts thereof wherein X is a carbonyl, sulfonyl, methylene, or methylene substituted with optionally substituted phenyl; Z is nitrogen or CH; Ar1 and Ar2 i

Substituted 1-aryl-3-piperazin-1'-yl propanones

Disclosed are compounds of formula I: STR1 wherein X is a carbonyl, sulfonyl, methylene, or methylene substituted with optionally substituted phenyl; Z is nitrogen or CH; Ar1 and Ar2 independently represent aryl groups; and Y is hydr